Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Biotech
CAMP4 is latest to eye IPO, while Upstream spells out $182M plan
RNA biotech CAMP4 has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its own IPO ambitions at $182 million.
James Waldron
Oct 7, 2024 8:44am
Pentixapharm scores $22M in IPO to advance radiopharma trials
Oct 3, 2024 10:36am
Zephyrm seeks Hong Kong IPO to fund phase 3 cell therapy trials
Oct 2, 2024 8:19am
BioAge brings in $198M from IPO as obesity biotech joins Nasdaq
Sep 26, 2024 4:44am
BioAge eyes $180M from IPO, private placement for obesity trials
Sep 25, 2024 7:55am
Inflammation-focused Upstream to join trickle of biotech IPOs
Sep 19, 2024 4:50am
